Rare disease biotech Rallybio cuts 19 staffers and sheds partnered preclinical programs
06 Feb 2024
Phase 2
Rallybio is
laying off
close to half of its employees and seeking “alternative options” for its preclinical programs as it gets ready to put the two lead candidates into Phase II.
Facing a
harsh funding environment
, Rallybio joins a wave of biotechs doubling down on their most advanced assets and shedding the rest to save costs. In total, it is cutting 19 employees, or 45% of the workforce.
In its case, the New Haven, CT-based biotech is betting on a pair of potential rare autoimmune disease treatments: RLYB212, an anti-HPA-1a antibody designed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB116, a once-weekly, low volume subcutaneously injected C5 inhibitor that will be tested for complement-mediated diseases. It expects to start a mid-stage trial for RLYB212 in pregnant women and come up with a development plan for RLYB116 at an optimized dose in the second half of the year.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.